Serum thyroglobulin concentrations predict disease‐free remission and death in differentiated thyroid carcinoma
- 9 November 2006
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 66 (1), 58-64
- https://doi.org/10.1111/j.1365-2265.2006.02685.x
Abstract
Objective Most studies on the diagnostic value of serum thyroglobulin (Tg) concentrations in differentiated thyroid carcinoma (DTC) use fixed cut‐off levels in heterogeneous groups of patients with respect to initial therapy and do not provide prognostic data. The objective was to investigate the prognostic values of serum Tg for disease‐free remission and death, measured at fixed time‐points after initial therapy using receiver operator characteristic (ROC) curve analyses. Design Single‐centre observational study with 366 consecutive patients with DTC, who had all been treated according to the same protocol for initial therapy and follow‐up. Methods Tg concentrations were measured at five fixed time‐points after initial surgery. Tg cut‐off values with the highest accuracy were calculated with ROC analyses. Results During the 8·3 ± 4·6 years of follow‐up, 84% of the patients were cured. Pre‐ablative Tg levels were an independent prognostic indicator for disease‐free remission (Tg cut‐off value 27·5 µg/l, positive predictive value 98%). The highest diagnostic accuracies of serum Tg for tumour presence were found during TSH‐stimulated Tg measurements, 6 months after initial therapy (Tg cut‐off value 10 µg/l; sensitivity 100%, specificity 93%). DTC‐related mortality was 14%. TSH‐stimulated Tg levels before ablation and 6 months after initial therapy were independent prognostic indicators for death. Conclusion Optimal institutional Tg cut‐off levels for diagnosis and prognosis should be defined using ROC analyses for each condition and time‐point. Tg measurements 6 months after initial therapy during TSH stimulation had an excellent diagnostic value. Tg levels are independent prognostic indicators for disease‐free remission and death. Using this strategy, high‐risk patient groups can be selected based on Tg levels, in addition to conventionally used prognostic indicators.Keywords
This publication has 27 references indexed in Scilit:
- Diagnostic value of serum thyroglobulin measurements in the follow‐up of differentiated thyroid carcinoma, a structured meta‐analysisClinical Endocrinology, 2004
- Prognostic Value of Thyroglobulin Serum Levels and 131I Whole-Body Scan after Initial Treatment of Low-Risk Differentiated Thyroid CancerThyroid®, 2004
- Laboratory Support for the Diagnosis and Monitoring of Thyroid DiseaseThyroid®, 2003
- Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?Clinical Endocrinology, 2002
- Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomasJournal of Surgical Oncology, 2002
- Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2001
- Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients with Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 1998
- Further Studies of Amino Acids (268–304) in Thyrotropin (TSH)-Lutropin/Chorionic Gonadotropin (LH/CG) Receptor Chimeras: Cysteine-301 Is Important in TSH Binding and Receptor Tertiary StructureThyroid®, 1994
- ROC analysis in radioimmunoassay: An application to the interpretation of thyroglobulin measurement in the follow-up of thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1987
- A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassayClinical Immunology and Immunopathology, 1985